Accueil>>Proteins>> Growth Factors>> Macrophage Migration Inhibitory Factor>>BRD32048

BRD32048

Catalog No.GC42975

BRD32048 est un liant direct d'ETV1 avec un KD de 17,1 μM. BRD32048 module À la fois l'activité transcriptionnelle induite par ETV1 et l'invasion des cellules cancéreuses induites par ETV1. BRD32048 inhibe l'acétylation d'ETV1 et favorise sa dégradation. BRD32048 agit comme un perturbagène ETV1 candidat de premier plan.

Products are for research use only. Not for human use. We do not sell to patients.

BRD32048 Chemical Structure

Cas No.: 433694-46-3

Taille Prix Stock Qté
500μg
37,00 $US
En stock
1mg
71,00 $US
En stock
5mg
214,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ETS variant 1 (ETV1) is a transcription factor oncogene implicated in several cancers where it has been altered by chromosomal translocation, gene amplification, or lineage dysregulation. The ETV1 transcription factor is phosphorylated downstream of MAPK signaling and is acetylated at lysines 33 and 116 by the histone acetyltransferase p300. Both of these events increase the protein half-life of ETV1 and enhance its transcriptional activity. BRD32048 is a substituted [1,3,5]triazine derivative that inhibits ETV1 transcriptional activity by binding to ETV1 (KD = 17.1 µM in vitro), which reduces p300-dependent acetylation and stability of ETV1 and, thereby, promotes its degradation. At 20-100 µM, BRD32048 can dose-dependently prevent invasion of ETV1-reliant cancer cells in in vitro models.

Avis

Review for BRD32048

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BRD32048

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.